etesevimab: Clinical Trials

4 trials of etesevimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 unknown. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Unknown 1

Follow etesevimab: new trials by email Literature Review of etesevimab trials Research Report on etesevimab

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19
JS026/placebo, JS016/placebo - COVID-19
Phase 1CompletedShanghai Junshi Bioscience Co., Ltd.482021-12-162023-08-01
A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
LY3832479, Placebo - Healthy
Phase 1CompletedEli Lilly and Company182020-11-022021-12-06
A Study of LY3832479 (LY-CoV016) in Healthy Participants
LY3832479, Placebo - Healthy
Phase 1CompletedEli Lilly and Company262020-06-192021-12-06
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
JS016 (anti-SARS-CoV-2 monoclonal antibody) - COVID-19; and High Infection Risk of SARS-CoV-2
Phase 1UnknownShanghai Junshi Bioscience Co., Ltd.402020-06-052020-06-22

Conditions studied

COVID-19 (2)

Sponsors

Eli Lilly and Company (2)  ·  Shanghai Junshi Bioscience Co., Ltd. (2)

Countries

China (2)  ·  United States (2)

Results publications

PMID 34473343, PMID 33972256